小儿肺热咳喘口服液治疗肺炎支原体气管炎、支气管炎的多中心疗效观察  

Multicenter clinical observation of Infantile Feirekechuan Oral Solution for treating mycoplasma pneumoniae tracheitis and bronchitis in children

作　　者：辛德莉[1] 王红[3] 秦选光[4] 周薇[5] 吴力群[6] 李静[7] 徐保平[8] 董艳[1] 胡文娟[1] 郭东星[1] 侯安存[2] 申昆玲[8] 

机构地区：[1]首都医科大学附属北京友谊医院热带病研究所,100050 [2]首都医科大学附属北京友谊医院儿科,100050 [3]民航总医院儿科,北京100025 [4]首都医科大学附属北京朝阳医院儿科,100020 [5]北京大学第三医院儿科,100000 [6]北京中医药大学附属东方医院儿科,100078 [7]北京市昌平区中西医结合医院儿科,102208 [8]首都医科大学附属北京儿童医院儿科,100045

出　　处：《中华实用儿科临床杂志》2016年第14期1101-1104,共4页Chinese Journal of Applied Clinical Pediatrics

摘　　要：目的观察小儿肺热咳喘口服液治疗肺炎支原体（MP）气管炎、支气管炎的临床疗效，为中药治疗儿童MP感染提供临床依据。方法本研究为前瞻性、随机、开放、平行、阳性药物对照的多中心临床观察。2014年9月至2015年4月期间，将符合人选标准的MP气管炎、支气管炎的患儿作为研究对象，随机分为治疗组和对照组，对照组应用阿奇霉素，治疗组应用小儿肺热咳喘口服液。收集所有患儿的临床资料、咽拭子标本。应用巢式PCR检测其咽拭子标本中MP23SrRNA。对PCR阳性的气管炎、支气管炎患儿的临床资料进行总结分析。结果符合入选标准、咽拭子MP—DNA阳性的气管炎、支气管炎患儿共118例。其中对照组59例，治疗组59例。23SrRNA的红霉素作用靶位的2063位点发生碱基突变患儿98例。其中对照组46例（占77．8％），治疗组52例（占88．1％）。对照组非耐药菌株13例，治疗组非耐药菌株7例。治疗结束时，治疗组患儿退热时间、咳嗽减轻及消失时间、咳痰减轻及消失时间均较对照组短，差异均有统计学意义（P均〈0．05）。治疗组治愈32例，显效15例，有效9例，有效率95．00％；对照组治愈28例，显效13例，有效12例，有救率89．90％。治疗组有效率和治愈率与对照组比较，差异均有统计学意义（P均〈0．05）。治疗后，对照组非耐药菌株的退热时间、咳嗽减轻及消失时间、咳痰减轻及？肖失时间均较耐药菌株短，差异均有统计学意义（P均〈0．05）。治疗后，治疗组患儿非耐药菌株的退热时间、咳嗽减轻及消失时间、咳痰减少及消失时间与耐药菌株比较差异均无统计学意义（P均〉0．05）。结论小儿肺热咳喘口服液对改善儿童MP感染引起的气管炎、支气管炎症状具有较好疗效，而且治疗耐药MP气管炎、支气管炎的效果优于阿奇霉素，为临床应用中医药治疗儿童MPObjective To observe the clinical curative effect of Infantile Feirekechuan Oral Solution in the treatment of mycoplasma pnenmoniae（MP） tracheitis, bronchitis, and to provide clinical basis for traditional Chinese medicine treatment of children MP infection. Methods This study was a prospective, randomized, open, parallel and positive drug - controlled multicenter clinical observation. During September 2014 to April 2015, the children with MP of tracheitis and bronchitis who met the inclusion criteria were selected as the research subjects, and they were randomly divided into treatment group and control group, the control group was given Azithromycin, the treatment group was given Infantile Feirekechuan Oral Solution. All the patient＇s clinical information, pharynx swab specimens were collected. The nested PCR was applied to detect pharyngeal swab specimens MP 23S rRNA, the clinical datas were summarized and analyzed in children with positive PCR. Results A total of 118 cases met the inclusion criteria, pharynx swab MPDNA positive tracheitis, bronchitis, 59 cases in the control group, and 59 cases in treatment group. There were 23S rRNA 2 063 sites of action of Erythromycin base mutation in 98 cases, among which 46 cases （77.8%） were in control group, and 13 cases of drug - resistant strains, and 52 cases in treatment group, accounting for 88.1%, and 7 cases of non - resistant strains. At the end of the treatment, compared with the control group, defervescence time, cough relief time and the elapse time,phlegm relief and the vanishing time were shorter of children in treatment group, and the differences were statistically significant（ all P 〈 0.05 ）. In treatment group ,32 cases were cured, 15 cases were markedly effective, effective in 9 cases,effective rate was 95.00% ;in control group,28 cases were cured, 13 cases were markedly effective, 12 cases effective, effective rate was 89.90%. Compared with control group ,the efficacy and recovery rates in treatment group were statistically different（

关 键 词：小儿肺热咳喘口服液 肺炎支原体 气管炎 支气管炎 

分 类 号：R725.6[医药卫生—儿科]